 |
|
|
| |
Ombitasvir/Paritaprevir/r and Dasabuvir With or Without Ribavirin for Patients With Post-Transplant HCV Recurrence
|
| |
| |
Reported by Jules Levin
66th Annual Meeting of the American Association for the Study of Liver Diseases, November 13-17, 2015, San Francisco, California
Parvez S Mantry1, Robert S Brown Jr2, Jeffrey V Enejosa3, Marina Berenguer4, Paul Y Kwo5, Kosh Agarwal6, Kimberly A Brown7, Norah A Terrault8, Jacqueline G O'Leary9, Michael P Manns10, Geoffrey W McCaughan11,
Didier Samuel12, Prajakta Badri3, Wangang Xie3, Carolyn Setze3, Tami Pilot-Mati as3, Nancy S Shulman3, Xavier Forns13
1The Liver Institute at Methodist Dallas, Dallas, Texas, United States; 2Columbia University Medical Center, Center for Liver Disease and Transplantation, New York, New York, United States; 3AbbVie Inc., North Chicago, Illinois, United States; 4La Fe University Hospital and CIBEREHD, Valencia, Spain;
5Indiana University, Indianapolis, Indiana, United States; 6Insti tute of Liver Studies, Kings College Hospital, London, United Kingdom; 7Henry Ford Health System, Detroit, Michigan, United States; 8University of California San Francisco, San Francisco, California, United States; 9Baylor University Medical Center, Dallas,
Texas, United States; 10Hannover Medical School, Dept. of Gastroenterology, Hepatology and Endocrinology, Hannover, Germany; 11AW Morrow Gastroenterology and Liver Centre Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; 12Hôpital Paul Brousse Centre Hépato-Biliaire, Villejuif, France; 13Liver Unit, Hospital Clinic, IDIBAPS, CIBEREHD, Barcelona, Spain
|
| |
|
|
|
|
|
